Fig. 2: Risk of Adverse Events within 28 Days Following XBB.1.5-containing COVID-19 mRNA Vaccination, Adjusted for COVID-19 Infection and Temporal Trends. | Nature Communications

Fig. 2: Risk of Adverse Events within 28 Days Following XBB.1.5-containing COVID-19 mRNA Vaccination, Adjusted for COVID-19 Infection and Temporal Trends.

From: Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study

Fig. 2

Notes: Each outcome was studied separately. Encephalitis was omitted because it was not observed with significant cases in this study. Events fewer than 20 were replaced with ‘< 20’ in accordance with N3C regulation. IRR indicates incidence rate ratio, calculated using conditional Poisson regression. The primary analysis included patients who received either brand of the XBB.1.5-containing COVID-19 mRNA vaccines and experienced specific outcomes. The model was adjusted for COVID-19 infection and temporal trends.

Back to article page